AbCellera Biologics acquired Trianni, Inc. for $90.0 million initial purchase price (plus a contingent earn-out with an estimated fair value of ~$22.6 million at close), a transaction completed in November 2020, structured as all cash — funded with $90.0 million of proceeds from convertible notes.
Trianni, Inc. operates in Antibody-discovery platform technology, is based in United States. Trianni develops genetically engineered transgenic mice for antibody discovery. Its flagship Trianni Mouse platform generates fully human monoclonal antibodies, giving AbCellera an in-house source of diverse, drug-like human antibodies to feed its microfluidic single-cell screening technology.
AbCellera acquired Trianni to add a proprietary humanized-mouse immunization source to its technology stack and to strengthen its ability to generate diverse panels of human antibodies with drug-like properties.
A validated humanized-mouse platform that produces fully human antibodies, complementing AbCellera's single-cell screening technology and adding recurring platform-licensing revenue. In-house transgenic-mouse antibody source integrated directly into AbCellera's discovery workflow, plus ongoing Trianni platform licensing revenue. Operated as an AbCellera company
With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies.Carl Hansen, Ph.D., CEO, AbCellera
Advisory firms were not disclosed for this transaction.